Pfizer Vs. Eli Lilly Stock – Which Is A Better Pick? (2024)

FAQs

Pfizer Vs. Eli Lilly Stock – Which Is A Better Pick? ›

We believe that Eli Lilly stock (NYSE: LLY) is currently a better pick than its industry peer – Pfizer stock , given its better prospects. PFE stock trades at a much lower multiple of 2.8x revenues, versus 23.5x for LLY, and we think this gap in valuation will remain wide in favor of Eli Lilly.

Eli Lilly currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period.

The average price target for Pfizer is $32.77. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $45.00 ,the lowest forecast is $27.00. The average price target represents 12.96% Increase from the current price of $29.01.

However, forecasts provide a positive outlook: the share price is expected to reach $30.10 by the end of 2024, showing annual growth of 4%. This means the price may grow 6% from the current levels to the end of the year, which confirms the potential for recovery and confidence in the company.

Analyst Price Targets

Based on analysts offering 12 month price targets for PFE in the last 3 months. The average price target is $32.77 with a high estimate of $45 and a low estimate of $27.

The 20 analysts with 12-month price forecasts for Eli Lilly stock have an average target of 930.75, with a low estimate of 610 and a high estimate of 1,125. The average target predicts an increase of 3.11% from the current stock price of 902.71.

Further, Eli Lilly stock fell after President Joe Biden and Sen. Bernie Sanders criticized the prices it and Novo Nordisk (NVO) charge for their obesity treatments, Zepbound and Wegovy. Lilly is also working on a next-generation weekly shot called retatrutide.

Significantly Cheaper Than the Overall Market

Pfizer's stock is down primarily because of the decline in revenue from its COVID business as the pandemic fades into the background, but there are other reasons for optimism, as we'll discuss later.

Based on short-term price targets offered by 19 analysts, the average price target for Pfizer comes to $33.21. The forecasts range from a low of $27.00 to a high of $45.00. The average price target represents an increase of 12.92% from the last closing price of $29.41.

With a forward dividend yield of roughly 5.9%, Pfizer definitely shouldn't be a stranger to income investors. CFO David Denton recently said that "sustaining and growing the dividend is number-one priority for us." Yes, Pfizer has some challenges. Its COVID-19 product revenue has fallen significantly.

What stock will boom in 2024? ›

Expert forecasts for Pfizer (NYSE: PFE) show a range of potential outcomes: by 2024, targets span $25.75 to $32.25, by 2025, $21.00 to $39.85, and by 2030, $44.00 to $108.00.

And thanks to Pfizer's own products and its series of acquisitions, the company sees potential for 2030 non-COVID revenue of as much as $84 billion, for a 10% compound annual growth rate from 2025 through 2030.

Pfizer has a consensus rating of Moderate Buy, which is based on 7 buy ratings, 11 hold ratings and 0 sell ratings.

Largest shareholders include BlackRock Inc., Vanguard Group Inc, State Street Corp, Bank Of America Corp /de/, Jpmorgan Chase & Co, Northern Trust Corp, Wellington Management Group Llp, Bank of New York Mellon Corp, Geode Capital Management, Llc, and Price T Rowe Associates Inc /md/ .

Eli Lilly (LLY) Stock Price Prediction in 2025

Of the 26 analysts covering Eli Lilly stock, the current rating is 1.71 or “Outperform” with 1-year price targets as high as $1,100 and as low as $540.00.

Yes, LLY has paid a dividend within the past 12 months. How much is Eli Lilly & Co's dividend? LLY pays a dividend of $1.3 per share. LLY's annual dividend yield is 0.53%.

There are no guarantees that Eli Lilly will split its shares this year or even five years from now. Stock splits aren't a necessity, after all. A stock can rise in value even if its share price is north of $1,000.

Eli Lilly's financial results are already exceptionally strong. In the first quarter, the company's revenue was $8.8 billion, a 26% year-over-year increase -- fantastic performance for a pharmaceutical giant.